VANCOUVER, British Columbia--(BUSINESS WIRE)--June 20, 2006--MIV Therapeutics, Inc. (OTCBB:MIVT - News; FWB:MIV), a leading developer of new generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, announced today that it has presented recent research progress on hydroxyapatite (HAp) coatings for stents, which indicated the Company’s proprietary coatings for coronary stents far outperformed technologies and products currently in use.
